Stanford researchers have developed a general system to regulate the activities of specific proteins in mammalian cells using cell-permeable, synthetic molecules.
Hematopoietic stem and progenitor cells, collectively "HSPCs", are multipotent cells that can self-renew and differentiate into all types of blood cells, including cells of both myeloid and lymphoid lineage.
Stanford researchers have demonstrated clinical proof of concept that a real-time biofeedback system can reduce pain and slow joint degeneration in patients with movement disorders such as knee osteoarthritis.
Stanford researchers have patented a system for precise genetic modification of human embryonic stem cells (ECSs) and induced pluripotent stem cells (iPSCs).
Current challenges in corneal endothelial cells (CEC) transplantation include the limited availability of donor grafts and the inability of CECs to regenerate within the body.
Researchers in Prof. Paul George's laboratory have patented a conductive polymer scaffold designed to electrically stimulate neural progenitor cells (NPCs) for enhanced neural regeneration.
Stem cells are generally influenced by a microenvironmental niche, typically comprised of epithelial and mesenchymal cells and extracellular substrates. Many attempts have been made to produce culture systems that mimic normal intestinal epithelial growth and differentiation.
Patients with celiac disease have a pathological reaction to gluten and have either HLA-DQ2+ (90%) or HLA-DQ8+, but expression of these MHC class II haplotypes is not sufficient and other factors are necessary for the development of celiac sprue.
Obtaining pure cell types from mixed cell populations continues to be a significant obstacle in the fields of stem cell biology and regenerative medicine.
A team of Stanford engineers has identified first-in-class epidermal growth factor (EGF) mutants with enhanced activity. These mutants can stimulate increased EGF receptor activation at 10-fold lower concentrations than wild-type EGF.